Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guominkang is a Traditional Chinese Medicine (TCM) granule formulation developed by the Beijing University of Traditional Chinese Medicine for the treatment of allergic rhinitis. It is designed to regulate the body's constitution and immune response to alleviate symptoms associated with allergic rhinitis. The drug is currently being evaluated in randomized controlled clinical trials (such as ChiCTR2300068155) to assess its efficacy, safety, and underlying mechanisms of action in patient populations. As a TCM product, it typically consists of a combination of botanical extracts intended to modulate inflammatory pathways and restore physiological balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guominkang (Beijing University of Chinese Medicine).